ALZ-002
- Generic Name
- ALZ-002
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients
Phase 1
Completed
- Conditions
- Spinal and Bulbar Muscular AtrophyKennedy's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- AnnJi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT05517603
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸National Institutes of Health, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath